Date: Thursday, June 23, 2016
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson’s disease (PD).
Background: α-syn plays a crucial role in the etiology of PD, the most common neurodegenerative movement disorder. Not only is misfolded α-syn a major constituent of Lewy Bodies, but elevated gene expression due to α-syn trisomy leads to inherited PD. Transmission of α-syn pathology is believed to contribute to disease progression. Immunotherapy against α-syn is thus a promising therapeutic approach for slowing disease progression.
Methods: We generated a recombinant human antibody against α-syn based on an endogenous antibody isolated from a de-identified library of B cells collected from healthy elderly subjects using a technology platform called Reverse Translational Medicine (RTM®). The biochemical and functional properties of this antibody (BIIB054) were characterized, including its binding selectivity and ability to inhibit α-syn transmission between primary neurons cultured in a microfluidic two-chamber system. The effects of BIIB054 on α-syn spreading in vivo were assessed in mouse models that were intracerebrally inoculated with preformed α-syn fibrils.
Results: BIIB054 displayed very high selectivity for α-syn aggregates relative to soluble monomeric recombinant α-syn, and specifically immunoprecipitated pathological α-syn from human disease brain. In cultured primary neurons BIIB054 reduced transmission of α-syn from neuron to neuron. Finally, in mouse models BIIB054 attenuated the transmission of α-syn pathology and rescued motor impairments.
Conclusions: Preclinical pharmacologic data on human-derived anti-α-syn antibody BIIB054 support its clinical development for the treatment and prevention of PD.
To cite this abstract in AMA style:A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb. Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo [abstract]. Mov Disord. 2016; 31 (suppl 2). http://www.mdsabstracts.org/abstract/human-derived-synuclein-antibody-biib054-binds-pathologic-forms-of-synuclein-and-attenuates-transmission-of-synuclein-in-vitro-and-in-vivo/. Accessed July 23, 2017.
« Back to 20th International Congress
MDS Abstracts - http://www.mdsabstracts.org/abstract/human-derived-synuclein-antibody-biib054-binds-pathologic-forms-of-synuclein-and-attenuates-transmission-of-synuclein-in-vitro-and-in-vivo/